Heyman Benjamin, Choi Michael, Kipps Thomas J
Division of Regenerative Medicine, Department of Medicine, UC San Diego Moores Cancer Center, UC San Diego, La Jolla, California 92093, USA.
Division of Hematology/Oncology, Department of Medicine, UC San Diego, La Jolla, California 92093, USA.
Case Rep Hematol. 2024 Feb 24;2024:7612622. doi: 10.1155/2024/7612622. eCollection 2024.
Hodgkin lymphoma variant of Richter's transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.
里氏转化霍奇金淋巴瘤变体（HvRT）是慢性淋巴细胞白血病（CLL）患者的一种罕见并发症，总体预后较差。我们报告了首例已知的采用本妥昔单抗、多柔比星、长春花碱和达卡巴嗪联合治疗（A+AVD）的HvRT患者病例系列。在我们的4例患者系列中，2例接受A+AVD治疗的HvRT患者获得了40和42个月的持久缓解，而另外2例患者病情进展并最终死亡。仍需要继续研究HvRT患者的最佳治疗方法。
